ipragliflozin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
010203020112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
It remains to be seen whether pancreatic β cell dysfunction in type 2 diabetic patients can be ameliorated just by correcting… (More)
Is this relevant?
2014
2014
Ipragliflozin (Suglat® [Japan]), an orally active, next-generation sodium-glucose transporter 2 (SGLT2) inhibitor, has been… (More)
Is this relevant?
2014
2014
Ipragliflozin is a novel and selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that induces sustained increases in… (More)
Is this relevant?
2014
2014
AIMS/INTRODUCTION In the present dose-response study, we evaluated the efficacy and safety of ipragliflozin (ASP1941), a novel… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
AIMS Ipragliflozin is a novel, selective inhibitor of sodium glucose co-transporter 2 (SGLT2 inhibitor) in clinical development… (More)
Is this relevant?
2013
2013
The sodium-glucose cotransporter 2 (SGLT2) is responsible for most glucose reabsorption in the kidney and has been proposed as a… (More)
Is this relevant?
2012
2012
AIMS To investigate the effect of ipragliflozin on the pharmacokinetics of sitagliptin, pioglitazone or glimepiride and vice… (More)
Is this relevant?
2011
2011
The pharmacological profile of ipragliflozin (ASP1941; (1S)-1,5-anhydro-1-C-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-d… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
BACKGROUND Hyperglycaemia is associated with serious complications, significant morbidity and death. Despite the availability of… (More)
Is this relevant?
2011
2011
BACKGROUND The sodium-dependent glucose co-transporter 2 (SGLT2) is a high-capacity, low-affinity transport system primarily… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?